Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Hayes leads Bayer consumer business development: Timothy Hayes, senior VP and region head for Bayer HealthCare's Consumer Care Division in North America, takes on an additional role leading the division's Global Business Development, including Rx-to-OTC switches. In addition to overseeing the region's OTC drug business, effective July 1 Hayes leads new business development for Consumer Care's global brand portfolio and markets, including identifying and analyzing new and emerging opportunities and developing short- and long-term strategic plans, the Morristown, N.J.-based company said July 12. Consumer business development also includes acquisitions and in-licensing, the Bayer Aspirin and Aleve marketer noted. A 30-year veteran of the consumer products industry, Hayes joined Bayer Consumer Care in 1992. He previously served as senior VP, Consumer Care U.S.A., was a Consumer Healthcare Products Association executive for more than a decade and was on the advisory board of the National Association of Chain Drug Stores

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts